tiprankstipranks
pc:congr

Congruence Therapeutics

Congruence Therapeutics is a computationally-driven biotechnology company focused on developing transformative small molecule correctors to address diseases caused by protein misfolding. Utilizing its proprietary Revenir™ drug discovery platform, Congruence is advancing a pipeline targeting high-value, genetically validated, and difficult-to-drug conditions such as MC4R-deficient genetic obesity, GBA1-driven Parkinson's disease, and Alpha-1 Antitrypsin Deficiency. The company collaborates with large pharmaceutical partners to discover treatments for solid tumors and metabolic diseases, leveraging its innovative approach to drug discovery.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$72M
Total Amount Raised$72M
Total Funding Rounds2
Total Funding Rounds2
Latest Funding Amount$40M
Latest Funding Amount$40M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Mar 19, 2026
Investment
$39.50M
Sep 04, 2025
Investment
$32.00M

Investors

Investor Name
Funding Round
Investment
Investment
Investment
Investment
Investment

Related News and Analysis